The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate.

The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.

Provided are combination therapies for treating and preventing relapse of a tumor and infectious diseases in a subject, as well as methods for use thereof. The combination therapies comprise an Hsp70 based pharmaceutical ingredient and at least one further immunotherapeutic agent that specifically inhibits and/or preferably binds to an immune checkpoint molecule or tumor immune microenvironment immune regulator. Furthermore, a kit and methods of using the combination therapies of the invention are described.

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

A method for inhibiting and/or treating cancer in a subject in need thereof is disclosed. The method can include administering to a subject an effective amount of an HSP90 inhibitor; and administering to the subject an effective amount of Granzyme A, thereby treating and/or inhibiting the cancer in the subject in need thereof. A composition including an effective amount of an HSP90 inhibitor and an effective amount of Granzyme A is also disclosed.

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.